What is Antiphospholipid / Hughes Syndrome

TL;DR: Antiphospholipid syndrome (APS), also known as Hughes Syndrome, is an autoimmune disorder where the immune system mistakenly attacks normal proteins in the blood, leading to an increased risk of abnormal blood clots in both arteries and veins. It is a chronic, systemic condition that can affect any organ system and is a significant cause of recurrent pregnancy loss and stroke in younger individuals.

What is Antiphospholipid / Hughes Syndrome?

Antiphospholipid / Hughes Syndrome is a condition characterized by a hypercoagulable state—meaning the blood is prone to clotting more easily than normal. While a healthy immune system produces antibodies to fight infections, individuals with Antiphospholipid / Hughes Syndrome produce "antiphospholipid antibodies." These antibodies target phospholipids, which are essential components of cell membranes. When these antibodies bind to these components, they trigger the blood to clot inappropriately, which can block blood flow to vital organs.

Which body systems are affected by Antiphospholipid / Hughes Syndrome?

Because blood vessels reach every part of the human body, the impact of Antiphospholipid / Hughes Syndrome is systemic. The most common clinical manifestations include:

• Vascular system: Deep vein thrombosis (DVT) in the legs, pulmonary embolisms, and strokes.


• Reproductive system: Recurrent miscarriages, stillbirths, or preeclampsia.


• Neurological system: Migraines, cognitive dysfunction ("brain fog"), and seizures.


• Dermatological system: Livedo reticularis, a lace-like, purplish discoloration of the skin.


• Cardiac system: Heart valve abnormalities and potential myocardial infarction (heart attack).

How are the subtypes of Antiphospholipid / Hughes Syndrome classified?

Clinicians generally categorize Antiphospholipid / Hughes Syndrome into two primary classifications based on the presence of other underlying conditions:

1. Primary Antiphospholipid / Hughes Syndrome: This occurs in individuals who do not have any other underlying autoimmune disease.


2. Secondary Antiphospholipid / Hughes Syndrome: This occurs in patients who already have another autoimmune condition, most commonly Systemic Lupus Erythematosus (SLE).


3. Catastrophic Antiphospholipid / Hughes Syndrome (CAPS): A rare and life-threatening subtype involving the rapid, simultaneous clotting in multiple organ systems, requiring immediate intensive care.

Who is typically affected by this condition?

Data regarding the exact prevalence of Antiphospholipid / Hughes Syndrome remains limited, but it is estimated to affect approximately 1 in 2,000 people globally. The condition is significantly more common in women than in men, with a ratio of approximately 5:1. While it can be diagnosed at any age, the most frequent age of onset is between 20 and 50 years old. Currently, 451 people within the DiseaseMaps.org community are living with this diagnosis, sharing their unique experiences and management strategies.

What makes Antiphospholipid / Hughes Syndrome unique?

Unlike other clotting disorders that are purely genetic (like Factor V Leiden), Antiphospholipid / Hughes Syndrome is an acquired autoimmune condition. It is distinguished by the "triple-test" criteria: the presence of lupus anticoagulant, anticardiolipin antibodies, and anti-beta-2 glycoprotein I antibodies. Differentiation from other clotting disorders is vital because the treatment typically involves long-term anticoagulation therapy rather than simple blood thinners used for other conditions.

Next steps

• Consult a board-certified rheumatologist or hematologist for specialized diagnostic testing.


• Maintain a detailed log of all unexplained blood clots or pregnancy complications to share with your specialist.


• Join the DiseaseMaps.org community to connect with other patients and access shared resources.


• Discuss the necessity of long-term blood-thinning medication (anticoagulants) with your medical team.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Antiphospholipid Syndrome.


• Orphanet: Antiphospholipid syndrome (ORPHA:80).


• OMIM (Online Mendelian Inheritance in Man): Antiphospholipid Syndrome (#601267).


• Hughes Syndrome Foundation: Patient Education and Clinical Resources.